Compare · IINN vs RMD
IINN vs RMD
Side-by-side comparison of Inspira Technologies Oxy B.H.N. Ltd. (IINN) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IINN and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $28.02B, about 1678.8x IINN ($16.7M).
- Over the past year, IINN is down 48.0% and RMD is down 21.7% - RMD leads by 26.3 points.
- IINN has been more active in the news (17 items in the past 4 weeks vs 7 for RMD).
- RMD has more recent analyst coverage (25 ratings vs 2 for IINN).
- Company
- Inspira Technologies Oxy B.H.N. Ltd.
- ResMed Inc.
- Price
- $0.38+0.51%
- $196.70+1.81%
- Market cap
- $16.7M
- $28.02B
- 1M return
- -34.36%
- -4.88%
- 1Y return
- -47.97%
- -21.68%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 17
- 7
- Recent ratings
- 2
- 25
Inspira Technologies Oxy B.H.N. Ltd.
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest IINN
- SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.
- QTREX Awarded Government Grant to Advance the World's First Native RF Dielectric Material for Quantum Computing
- SEC Form F-3 filed by Inspira Technologies Oxy B.H.N. Ltd.
- Chief Technology Officer Yechezkely Hayon Daniella sold $150,000 worth of Ordinary Shares (50,000 units at $3.00), decreasing direct ownership by 6% to 780,000 units (SEC Form 4)
- Chief Financial Officer Tehila Yafit sold $105,019 worth of Ordinary Shares (30,000 units at $3.50) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 870,000 units (SEC Form 4)
- COO and VP of R&D Shabtay Abraham exercised 95,239 units of Ordinary Shares at a strike of $3.37, increasing direct ownership by 8% to 1,332,713 units (SEC Form 4)
- QTREX to Showcase Functional AME-Based Monolithic Connectivity Components for Quantum Computing Systems at Quantum.Tech World 2026 in Boston
- SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.
- SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.
- QTREX Secures Purchase Order from a U.S.-based Fortune 500 company for an AME System and Related Materials
Latest RMD
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $968,064 worth of ResMed Common Stock (4,991 units at $193.96) as part of a pre-agreed trading plan, increasing direct ownership by 0.01% to 466,256 units (SEC Form 4)
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)
- Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
- Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
- SEC Form SD filed by ResMed Inc.
- Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
- Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,037,233 worth of ResMed Common Stock (4,991 units at $207.82) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 3 filed by new insider Bloomer Aaron
- SEC Form 4 filed by Chief Financial Officer Sandercock Brett